ASCO's Richard Schilsky On State-of-the-Art Oncology Trials
ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.
You may also be interested in...
Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.
Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.
Combinations of checkpoint inhibitors and targeted drugs are said to hold the key to better, more durable results in the future. But recent studies highlighted some big challenges, like unexpected toxicities, prompting a call for more preclinical research to better predict winning combinations.